CytoDyn Inc CEO Nader Pourhassan talks to Proactive about results from the 350 mg weekly dose of its Phase 2 NASH clinical trial.
The Vancouver, British Columbia-based company said that the trial was conducted in two parts. Part one compared a 700 mg weekly dose and placebo in a double-blind randomized manner and Part two evaluated a 350 mg weekly dose as an open-label study compared to the same placebo blinded arm. Pourhassan also updated on its HIV, TNBC, and critically ill coronavirus indications.
source